STADA and mAbxience enter into negotiations over adalimumab biosimilar

November 24, 2014 7:17 AM

STADA Arzneimittel AG and the biotech specialist mAbxience have agreed to negotiate over the in-licensing of an adalimumab (Humira®) biosimilar.

The letter of intent stipulates that the two negotiating parties will come to a decision within the next six months. The original product, Humira is the world’s top-selling biopharmaceutical with a sales volume in 2013 of approximately 10.66 billion US dollars in 2013.

With these negotiations, STADA continues its longstanding strategy of targeted in-licensing of selected biosimilars; a strategy with which the Group is continuously expanding its portfolio of quality products at comparably favorable conditions.

mAbxience is a fast-growing, fully-integrated biotech company specialized in research, development and manufacturing of biosimilars. Through its business model, its five products in development will have a global presence in over 50 countries. It is planned to develop and manufacture the biosimilar adalimumab at the Genhelix biopharmaceutical plant located in Leon, Spain.

Due to the fact that numerous blockbuster biologics, including adalimumab, will lose their patent protection in the next few years, it can be assumed that biosimilars, as high-quality yet cheaper alternatives to the original products, will be even more important for patient care in the future.

Source: Stada press release

Comments are closed

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!